Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Generic Versions Of Copaxone Take Toll On Teva 3Q Results

By Mike Botta | November 3, 2017

Teva Reports Third Quarter 2017 Financial Results

Citing earlier than expected competition from generic versions of Copaxone, Teva Pharmaceuticals Industries Ltd. reported that its generic drug profits fell to $619 million from $982 million in the third quarter ending Sept. 30, 2017 with sales down to $3.01 billion from $3.26 billion.

Overall third quarter earnings per share fell to $1.00 from $1.31 during the year earlier period. The company also lowered its outlook for the year to $3.77 per sare from the earlier expectation of $3.87 per share.

Teva said its U.S. revenues of $1.2 billion were down 9% compared to the third quarter of 2016, mainly due to challenging market dynamics including pricing declines resulting from customer consolidation into larger buying groups and accelerated FDA approvals for additional generic versions of competing off-patent medicines.

Global revenues of Copaxone (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, were $1.0 billion, a decrease of 7% compared to the third quarter of 2016, according to the company.

Last month, the FDA approved a generic version of Copaxone 40 mg /mL and an additional generic version of Copaxone 20 mg/mL. A generic version of Copaxone 40 mg /mL was launched in the U.S. market. In the EU, a hybrid version of Copaxone 40 mg/mL was approved.

Teva’s Copaxone revenues in the United States fell to $802 million, a decrease of 8% compared to the third quarter of 2016, due to lower volumes of Copaxone 20 mg/mL, negative net pricing effects, mainly as a result of an increase in managed care rebate accruals for inventory in the channel following the FDA approvals for additional generic competition, partially offset by a price increase of 7.9% in January 2017 for both the 20 mg/mL and 40 mg/mL versions.

At the end of the third quarter of 2017, according to September 2017 IMS data, Teva’s U.S. market shares for the Copaxone products in terms of new and total prescriptions were 25.6% and 28.7%, respectively. Copaxone 40 mg/mL accounted for more than 85% of total Copaxone prescriptions in the U.S.

Copaxone revenues outside the United States were $185 million, down 1%, compared to the third quarter of 2016. Over 75% of European Copaxone prescriptions are now filled with the 40 mg/mL version.

The company also reported that its global Azilect revenues were $36 million, a decrease of 64% compared to the third quarter of 2016 following the introduction of generic competition to Azilect in the United States in 2017.

(Sources: Teva Pharmaceuticals Industries; FirstWord Pharma; Globes)


Filed Under: Drug Discovery

 

Related Articles Read More >

Recursion Pharmaceuticals Logo
Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design
Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE